Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남은미 | * |
dc.date.accessioned | 2016-08-27T04:08:19Z | - |
dc.date.available | 2016-08-27T04:08:19Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 0344-5704 | * |
dc.identifier.issn | 1432-0843 | * |
dc.identifier.other | OAK-14714 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/217099 | - |
dc.description.abstract | We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy. Patients treated with gemcitabine-based palliative treatment were enrolled in this study. Patients were received modified FOLFOX3 (mFOLFOX3) consists of oxaliplatin 85 mg/m(2) (day 1) and leucovorin 30 mg (days 1, 2) followed by 5-fluorouracil 1,500 mg/m(2) (days 1, 2) every 2 weeks. Between March 2010 and June 2012, a total of 30 patients were enrolled in this study. Twenty-eight patients were measurable for treatment response. One achieved complete response, and one a partial response was observed. Overall response rate was 7.1 % (95 % confidence interval 0.9-23.5 %). The median progression-free survival was 1.6 months, and the median overall survival was 4.4 months. Grade 3-4 hematologic toxicities included neutropenia (6.7 %) and thrombocytopenia (3.4 %). The most common non-hematologic toxicity was neuropathy (22.2 %). However, the most common grade 3-4 non-hematologic toxicity was hyperbilirubinemia (5.0 %). There was one treatment-related death due to neutropenic infection. mFOLFOX3 as a second-line regimen has modest effect and tolerable toxicity in unresectable/metastatic biliary tract cancer patients who have been treated previously via gemcitabine-based chemotherapy. | * |
dc.language | English | * |
dc.publisher | SPRINGER | * |
dc.subject | Biliary tract cancer | * |
dc.subject | Second line | * |
dc.subject | Fluorouracil | * |
dc.subject | Oxaliplatin | * |
dc.title | Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 75 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 757 | * |
dc.relation.lastpage | 762 | * |
dc.relation.journaltitle | CANCER CHEMOTHERAPY AND PHARMACOLOGY | * |
dc.identifier.doi | 10.1007/s00280-015-2691-1 | * |
dc.identifier.wosid | WOS:000351549100011 | * |
dc.author.google | Hwang, In Gyu | * |
dc.author.google | Jang, Joung-Soon | * |
dc.author.google | Oh, Sung Yong | * |
dc.author.google | Rho, Myung Hwan | * |
dc.author.google | Lee, Suee | * |
dc.author.google | Park, Young Suk | * |
dc.author.google | Park, Joon Oh | * |
dc.author.google | Nam, Eun Mi | * |
dc.author.google | Lee, Hyo Rak | * |
dc.author.google | Jun, Hyun Jung | * |
dc.author.google | Chi, Kyong-Choun | * |
dc.contributor.scopusid | 남은미(7005824288;57226666155) | * |
dc.date.modifydate | 20240301081003 | * |